Small Molecule Development & Manufacturting at Quotient Sciences

CMC Strategies to Manage the Risks Associated with Accelerated Submission Pathways

30 May 2024
Overview

There has been a growing need for the development of new treatments to address rare diseases, which often have limited or even no viable treatment options available. Since the signing of the Orphan Drug Act into law in the United States in 1983, the US Food and Drug Administration (FDA) has given special consideration to companies, providing “Fast Track status,” awarding research grants, and providing other incentives when certain criteria are met. These offer advantages to streamline the development of new therapies to treat rare diseases, and similar standards also exist in the United Kingdom and European Union. The acceleration of the clinical program reduces overall drug development timelines, which can bring CMC challenges along the way.

Join our speaker Dr. Asma Patel, Vice President of Integrated Development Services, as she delves into the different ways that global agencies have implemented accelerated regulatory pathways to expedite the development of novel therapies to treat serious diseases. Dr. Patel will discuss navigating the pathways for accelerated submission, exploring the regulatory framework as it relates to orphan drugs for rare diseases. She will discuss CMC strategies to manage the risks associated with accelerated submission pathways, up to and including the scale-up and commercial manufacturing of drug products.

What you will learn:

  • How to identify creative development strategies for accelerated submission pathways, from early clinical studies through to commercial launch.

Unable to attend due to a scheduling conflict?  Register now and we will share the content with you afterwards.

In partnership with: 

Register
Times

May 30, 2024

7:00 AM PST, 10:00 AM EST, 3:00 PM BST

Meet our speaker:

Dr. Asma Patel

VP, Integrated Development Services

Dr. Asma Patel is VP of Integrated Development Services at Quotient Sciences. In this role, Asma is responsible for providing scie...

About Asma

More insight from our experts:

Read More
Scientific Innovation, Modified Release, Translational Pharmaceutics Drug Development Innovation: 3D printing of pharmaceutical dosage forms – has the time come? By: Dr. Asma Patel
Read More